Infliximab in the treatment of tislelizumab-induced steroid-refractory immune checkpoint inhibitor-related pneumonia: case report and literature review

BACKGROUND: Infliximab has been recommended by the American Society of Clinical Oncology (ASCO) guidelines for the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonia (CIP), but clinical evidence remains insufficient. In order to improve the level of diagnosis and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhujun, He, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552064/
https://www.ncbi.nlm.nih.gov/pubmed/36237233
http://dx.doi.org/10.21037/tcr-22-1162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552064/
https://www.ncbi.nlm.nih.gov/pubmed/36237233
http://dx.doi.org/10.21037/tcr-22-1162

Ejemplares similares